A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma

Inclusion Criteria

• Between 18 and 70 years of age inclusive, at the time of signing the informed consent.
• Documented history of bronchial asthma, first diagnosed at least 6 months prior to the screening visit and currently being treated only with an intermittent short acting beta 2 agonist (SABA) or other non-corticosteroid controllers. Non corticosteroid controllers (e.g. leukotriene receptor antagonists [LTRAs]) must be discontinued from Screening until the end of Treatment Period 2.
• Able to replace current SABA treatment with salbutamol metered dose inhaler (MDI) at Screening for use as needed for the duration of the study. Judged capable of withholding salbutamol for at least 4 hours prior to FEV1 assessments.
• No use of an ICS or LABA for at least 12 weeks prior to first dose of study medication.
• A best pre-bronchodilator FEV1 >=60 percent (%) of the predicted normal value at screening.
• FEV1 increase by >=12% and >=200 milliliter (mL) over baseline value within 10-40 minutes of inhalation of 400 mcg salbutamol MDI (a spacer device may be used if required).
• Positive skin prick test to common aero-allergen(s) at screening (not historical).
• Sputum sub-study only: Able to produce >100 milligram (mg) of sputum at screening or during the run-in period.
• Body weight >=45 kilogram (kg) and body mass index (BMI) within the range 18-32 kilogram per meter square (kg/m^2) (inclusive).
• Male subject: Male subjects with female partners of child bearing potential must comply with the following contraception requirements from the first dose of study medication until completion of the follow-up visit.
• Vasectomy with documentation of azoospermia.
• Male condom plus partner use of one of the contraceptive options below:

Contraceptive subdermal implant with a 2x upper limit of normal (ULN) and bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin 450 millisecond (msec) or QTc >480 msec in subjects with bundle branch block.

• Other laboratory abnormalities or concurrent diseases/clinical: clinically significant laboratory abnormality, uncontrolled condition or disease state that, in the opinion of the investigator (in consultation with the GSK Medical Monitor, if required), would put the safety of the subject at risk through study participation or would confound the interpretation of the efficacy results if the condition/disease exacerbated during the study.
• Use of any of the prohibited medications listed in the protocol.
• Current smokers or subjects with a history of smoking within 6 months of screening, or with a total pack year history of >5 pack years.
• History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 gram (g) of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
• History of sensitivity to any of the study medications, or components thereof (including lactose) or a history of drug or other allergy (including a milk protein allergy) that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
• Sputum sub-study only: History of sensitivity to the induced sputum procedure.
• Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study medication.
• Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 56 days.
• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dose of study medication in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
• Exposure to more than 4 investigational medicinal products wi